Envestnet Asset Management Inc. increased its position in shares of Haleon plc (NYSE:HLN – Get Rating) by 44.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,582,499 shares of the company’s stock after buying an additional 484,359 shares during the period. Envestnet Asset Management Inc.’s holdings in Haleon were worth $12,660,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Tompkins Financial Corp purchased a new stake in Haleon during the 4th quarter worth $31,000. CKW Financial Group acquired a new position in shares of Haleon in the 3rd quarter valued at about $26,000. Glassman Wealth Services boosted its holdings in shares of Haleon by 1,052.6% in the 4th quarter. Glassman Wealth Services now owns 4,518 shares of the company’s stock valued at $36,000 after buying an additional 4,126 shares during the period. Assetmark Inc. acquired a new position in shares of Haleon in the 3rd quarter valued at about $29,000. Finally, Hudock Inc. acquired a new position in shares of Haleon in the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.
Analyst Ratings Changes
Several research firms have recently commented on HLN. Investec began coverage on shares of Haleon in a report on Thursday, February 23rd. They issued a “sell” rating for the company. Sanford C. Bernstein started coverage on shares of Haleon in a report on Tuesday, April 4th. They issued an “outperform” rating for the company. Argus raised shares of Haleon from a “hold” rating to a “buy” rating in a research note on Thursday, April 6th. Finally, Barclays boosted their target price on shares of Haleon from GBX 360 ($4.54) to GBX 364 ($4.59) in a research note on Tuesday, January 31st. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Haleon presently has an average rating of “Hold” and a consensus price target of $364.00.
Haleon Price Performance
Haleon Announces Dividend
The business also recently declared a — dividend, which was paid on Thursday, April 27th. Shareholders of record on Friday, March 17th were given a dividend of $0.0577 per share. The ex-dividend date of this dividend was Thursday, March 16th. This represents a dividend yield of 0.7%.
Haleon Company Profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
- Get a free copy of the StockNews.com research report on Haleon (HLN)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.